Over and over again, investors who follow the med-tech space will see
examples of companies generating solid revenue and profit growth in
markets that are seen as slow-growth. In the case of Masimo (MASI),
the company has used strong technology to add some spice to the pulse
oximetry market. More recently, though, the company has struggled to
generate the hoped-for growth from hemoglobin monitoring. Better
execution here is the real key to the story - if Masimo can translate
the potential of noninvasive hemoglobin monitoring into real sales,
there could be upside to these shares.
Please continue here:
Masimo Needs Rainbow To Lead To A Pot Of Gold
No comments:
Post a Comment